Methamphetamine inhibits toll-like receptor 9-mediated anti-HIV activity in macrophages

AIDS Research and Human Retroviruses

Volumn 29, Issue 8, 2013, Pages 1129-1137

  Cen, Ping ^a,b   Ye, Li ^c   Su, Qi Jian ^d   Wang, Xu ^a   Li, Jie Liang ^a   Lin, Xin Qin ^b   Liang, Hao ^c,d   Ho, Wen Zhe ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Nanning Center for Disease Control and Prevention   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

^d RUIKANG HOSPITAL AFFILIATED TO GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; INTERFERON REGULATORY FACTOR 7; METHAMPHETAMINE; MYELOID DIFFERENTIATION FACTOR 88; MYXOVIRUS RESISTANCE PROTEIN A; TOLL LIKE RECEPTOR 9;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; INNATE IMMUNITY; MACROPHAGE; PRIORITY JOURNAL; VIRUS REPLICATION;

ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERON-ALPHA; MACROPHAGES; METHAMPHETAMINE; MYELOID DIFFERENTIATION FACTOR 88; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; VIRUS REPLICATION;

EID: 84880563449     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0264     Document Type: Article

References (46)

1. Buchacz K. McFarland W. Kellogg T, et al.. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS 2005;19. 1423-1424.
2. Urbina A and Jones K. Crystal methamphetamine, its analogues, and HIV infection. Medical and psychiatric aspects of a new epidemic. Clin Infect Dis 2004;38:890-894.
3. Halkitis PN, Fischgrund BN, and Parsons JT. Explanations for methamphetamine use among gay and bisexual men in New York City. Subst Use Misuse 2005;40:1331-1345.
4. Shoptaw S, Reback CJ, and Freese TE. Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles. J Addict Dis 2002; 21:91-105.
5. Wang X, Wang YZ, Ye L, et al.. Modulation of intracellular restriction factors contributes to methamphetamine-mediated enhancement of acquired immune deficiency syndrome virus infection of macrophages. Curr HIV Res 2012;10:407-414
6. Potula R, Hawkins BJ, Cenna JM, et al.. Methamphetamine causes mitochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol 2010;185:2867-2876.
7. In SW, Son EW, Rhee DK, et al.. Methamphetamine administration produces immunomodulation in mice. J Toxicol Environ Health A 2005;68:2133-2145.
8. Mahajan SD, Hu Z, Reynolds JL, et al.. Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells. Implications for HIV-1 pathogenesis. Mol Diagn Ther 2006;10:257-269.
9. Liang H, Wang X, Chen H, et al.. Methamphetamine enhances HIV infection of macrophages. Am J Pathol 2008;172:1617-1624.
10. Hemmi H, Takeuchi O, Kawai T, et al.. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
11. Vollmer J, Jurk M, Samulowitz U, et al.. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res 2004;10:431-438.
12. Liu YJ. IPC. Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
13. Sadler AJ and Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559-568.
14. Baca-Regen L, Heinzinger N, Stevenson M, et al.. Alpha interferon-induced antiretroviral activities. Restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. J Virol 1994;68:7559-7565.
15. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
16. Yu P, Lü bben W, Slomka H, et al.. Nucleic acid-sensing Tolllike receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors.Immunity 2012;37(5):867-879.
17. Becker Y. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations- a review, hypothesis and implications. Virus Genes 2005;30:251-266.
18. Malaspina A, Moir S, DiPoto AC, et al.. CpG oligonucleotides enhance proliferative and effector responses of B cells in HIV-infected individuals. J Immunol 2008;181:1199-1206.
19. Hassan NF, Campbell DE, and Douglas SD. Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods 1986;95:273-276.
20. Schepers RJ, Oyler JM, Joseph RE Jr, et al.. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 2003;49:121-132.
21. Melega WP, Cho AK, Harvey D, et al.. Methamphetamine blood concentrations in human abusers. Application to pharmacokinetic modeling. Synapse 2007;61:216-220.
22. Guo CJ, Li Y, Tian S, et al.. Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med 2002;50:435-442.
23. Ho WZ, Lioy J, Song L, et al.. Infection of cord blood monocyte-derived macrophages with human immunodeficiency virus type J Virol 1992;66:573-579.
24. Li Y, Zhang T, Douglas SD, et al.. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003;163:1167-1175.
25. Mü ller T, Hamm S, and Bauer S. TLR9-mediated recognition of DNA. Handb Exp Pharmacol 2008;(183):51-70.
26. Nowroozalizadeh S, Jansson M, Adamsson J, et al.. Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin. Curr HIV Res 2008;6:230-238.
27. Winckelmann AA, Munk-Petersen LV, Rasmussen TA, et al.. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One 2013;8(4):e62074.
28. Beignon A S, McKenna K, Skoberne M, et al.. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005;115:3265-3275.
29. Meier A, Alter G, Frahm N, et al.. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 2007;81:8180-8191.
30. Ellis RJ, Childers ME, Cherner M, et al.. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003;188:1820-1826.
31. Marcondes MC, Flynn C, Watry DD, et al.. Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol 2010;177:355-361.
32. Abel K, Wang Y, Fritts L, et al.. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol 2005; 12:606-621.
33. Chaturvedi A and Pierce SK. How location governs toll-like receptor signaling. Traffic 2009;10(6):621-628.
34. Nishiya T, Kajita E, Miwa S, et al.. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J Biol Chem 2005;280(44):37107-37117.
35. Leifer CA, Brooks JC, Hoelzer K, et al.. Cytoplasmic targeting motifs control localization of toll-like receptor J Biol Chem 2006;281(46):35585-35592.
36. Pitha PM. Innate antiviral response. Role in HIV-1 infection. Viruses 2011;3(7):1179-1203.
37. Honda K, Yanai H, Mizutani T, et al.. Role of a transductional- transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA 2004;101:15416-15421.
38. Kawai T, Sato S, Ishii KJ, et al.. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004;5:1061-1068.
39. Uematsu S, Sato S, Yamamoto M, et al.. Interleukin-1 receptor-associated kinase-1 plays an essential role for Tolllike receptor (TLR)7-and TLR9-mediated interferon-{alpha} induction. J Exp Med. 2005;201:915-923.
40. Hemmi H, Kaisho T, Takeda K, et al.. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 2003;170:3059-3064.
41. Haller O and Kochs G. Human MxA protein. An interferoninduced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011;31:79-87.
42. Haller O, Staeheli P, and Kochs G. Protective role of interferon-induced Mx GTPases against influenza viruses. Rev Sci Tech 2009;28:219-231.
43. Chieux V, Hober D, Harvey J, et al.. The MxA protein levels in whole blood lysates of patients with various viral infections. J Virol Methods 1998;70:183-191.
44. Na H, Acharjee S, Jones G, et al.. Interactions between human immunodeficiency virus (HIV)-1 Vpr expression and innate immunity influence neurovirulence. Retrovirology 2011;8:44.
45. Randall RE and Goodbourn S. Interferons and viruses. An interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89:1-47.
46. Kumar S, Jaffar-Bandjee MC, Giry C, et al.. Mouse macrophage innate immune response to chikungunya virus infection. Virol J 2012;9:313.